Alcon's stock rallied following the release of second-quarter 2026 results, rising 4.8% to CHF 61.14 as markets reacted to a clear earnings beat and a more optimistic outlook for the full year. The company published results after the market close in the prior session, and investors responded to a combination of stronger operating metrics and a reduced tariff forecast.
Quarterly performance
On an adjusted basis, diluted earnings per share came in at $0.84, comfortably above the consensus estimate of $0.76 - an outperformance of roughly 11%. Net sales totaled $2.78 billion, an increase of about 8% year-over-year that modestly topped analyst expectations. These underlying operating results were the primary driver of investor enthusiasm.
Despite the adjusted beat, GAAP diluted EPS was reported as zero for the quarter after the company recorded a $402 million non-cash pre-tax impairment charge. That charge stems from the decision to discontinue the PowerVision accommodating lens program. Market participants appeared to treat this as a one-time accounting item and focused on the recurring performance when valuing the shares.
Guidance and outlook revisions
Management raised full-year guidance for core EPS growth to a range of 12% to 15% in constant currency. Alongside the EPS upgrade, the company expanded its target for full-year core operating margin improvement to a range of 90 to 190 basis points. Together these revisions signaled confidence in the underlying business trends for the remainder of the year.
Alcon also materially trimmed its estimated annual tariff headwind to a range of $40 million to $90 million, down from a prior estimate of $100 million to $150 million. The updated outlook incorporates an anticipated refund of approximately $60 million from the U.S. government, which contributed to the narrower tariff estimate.
Business drivers
The Surgical segment delivered notable momentum, with equipment sales up 26% amid the rollout of the Unity platform. Vision Care also posted healthy results as demand for Tryptyr and Systane dry eye products supported 13% growth in ocular health. These product-level drivers underpinned the company’s ability to lift guidance and point to improving operational performance across key franchises.
Market context
The broader market backdrop was neutral to supportive for the move. The Swiss Market Index traded in positive territory while U.S. gauges were broadly steady - the S&P 500 was essentially unchanged and the Nasdaq was marginally positive - meaning macro conditions did not offset the company-specific catalysts. Peers in the eye care sector, including The Cooper Companies, operate in a growing market that benefited from aging demographics and rising demand for surgical eye procedures, lending context to Alcon’s confidence in its upgraded outlook.
Investor reaction and valuation considerations
Alcon’s shares remain well below their 52-week high of CHF 72.88, having traded as low as CHF 47.80 over the past year. The majority of covering analysts continue to hold positive ratings on the stock, and today’s results gave market participants fresh reason to reassess the valuation gap relative to peers and the company’s revised targets.
In sum, an earnings beat on adjusted EPS and sales, a materially improved tariff outlook that includes an expected U.S. refund, and raised full-year guidance for EPS growth and margin expansion combined to produce the rally in the equity. While a sizeable non-cash impairment affected GAAP EPS for the quarter, investors focused on the recurring operating trends when pricing the stock.